NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. (Q30352718)

20 June 2017

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection. (English)

1 reference

20 June 2017

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

1 reference

2

K Rajender Reddy

1 reference

20 June 2017

D Alan Herbst

1

1 reference

PubMed ID

23931586

20 June 2017

language of work or name

English

0 references

publication date

9 August 2013

1 reference

Expert Opinion on Investigational Drugs

20 June 2017

1 reference

20 June 2017

22

1 reference

20 June 2017

10

1 reference

20 June 2017

1337-1346

1 reference

Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium

20 June 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Response-guided telaprevir combination treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Hepatitis C virus NS5A: tales of a promiscuous protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

NS5A--from obscurity to new target for HCV therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Identification of Hepatitis C Virus NS5A Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Preliminary study of two antiviral agents for hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.826189

10.1517/13543784.2013.826189

21 January 2018

Identifiers

DOI

1 reference

20 June 2017

1 reference

PubMed ID

23931586